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ABSTRACT 
 
EFFECTS OF ISCHEMIC PRECONDITIONING ON EXERCISE ECONOMY 
GUNGEET KAUR 
2016 
 
Ischemic preconditioning (IPC) is the application of small bouts of ischemia 
followed by reperfusion. IPC has shown to enhance exercise performance in varied sports 
like 5K running, cycling and swimming. However, effect of ischemic preconditioning on 
running economy have not be investigated so far. We proposed that bilateral ischemic 
preconditioning will improve running economy in young healthy people. Methods: The 
study was a randomized single- blinded crossover study. Nineteen men and women were 
included in the study. Each participant underwent a sham and IPC trial using high 
pressure cuff (EC20 rapid cuff inflator, DE Hokanson, Inc.) followed by running 
economy trial (Parvo Medics, TrueOne 2400) of 15 minutes. The sham or IPC trial 
consisted of 3X 5 min of bilateral leg ischemic at pressure of 15 mm of Hg (sham) or 220 
mm of Hg (IPC). Each 5 min stage of bilateral leg ischemia was followed by 5 minutes of 
reperfusion which was followed by 3X 5 min of submaximal treadmill running. Results 
The data was completed and analyzed for 18 subjects. The mean age of participants was 
27+7 years with BMI for all subjects was 24.6± 3.0 kg/m2. A two way ANOVA was used 
to assess interaction in running economy (i.e., steady-state oxygen consumption, 
respiratory exchange ratio, heart rate) in the absence and presence of IPC. In the sham 
running trial, oxygen consumption progressively increased 22% (P<0.001) from 34.1 
(stage 1) to 41.6 ml/kg/min (stage 3) and 20% (P<0.001) from 34.3 (stage 1) to 
41.4 ml/kg/min (stage 3) in the IPC running trial. There was no time X trial interaction in 
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steady-state oxygen. Running economy showed no significant change during the sham 
running trial, (P=0.232) from 201.6 (stage 1) to 204.0 ml/kg/km (stage 3). The same trend 
in running economy was observed during the IPC trial (P=0.129; from 202.8 to 203.1 
ml/kg/km). There was no time X trial interaction (P=0.647) in running economy. 
Additionally heart rate showed a general increase from 152±9 (stage 1) to174±6 (stage 3) 
for the sham trials and 151±11 (stage 1) to 174±8 (stage 3) for IPC trials. We did not find 
significant differences in heart rate during sham and IPC trials (P= 0.999). Conclusion: 
The present study did not supported our hypothesis that remote IPC can improve running 
economy. 
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1: INTRODUCTION 
 
When the blood supply to the heart is restored after a prolonged period of ischemia, 
as for example with the use of thrombolytic therapy or primary percutaneous tissue injury 
intervention to treat an acute myocardial infarction, reperfusion causes tissue injury. This 
process is referred to as myocardial ischemic/reperfusion (I/R) injury which can lead to 
cardiac arrhythmias, ventricular dysfunction and even myocardial cell death (Luca, Liuni, 
McLaughlin, Gori, & Parker, 2013). As a result, reperfusion injury is thought to 
adversely contribute to clinical outcomes after myocardial infarction, particularly by 
increasing the severity of tissue damage and rate of recurrent thrombotic events despite 
optimal reperfusion therapy. The severity of reperfusion injury depends on the duration 
of ischemia. Short bouts of ischemia (1-5 min) can cause reversible cell dysfunction and 
electrical disturbances in the cells. Ischemia beyond duration of 5 min elicits more severe 
cell damage and can lead to tissue death (Hausenloy & Yellon, 2008; 1. 
The mechanisms underlying I/R injury are not fully understood. Due to the lack of 
oxygen and inability to meet aerobic energy requirements there is a depletion of cellular 
ATP. The ischemia leads to increased anaerobic metabolism for energy production which 
decreases the intracellular pH. In addition, the lack of ATP inhibits sodium potassium 
ATPase and ATP-dependent calcium reuptake in sarcoplasmic reticulum. This leads to an 
increase in calcium concentrations which in turn results in myocardial calcium overload. 
Restoration of the blood flow reinstates the normal cellular functions and ATP 
generation; however with more extensive ischemia leads to mitochondrial membrane 
destabilization (Tapuria et al., 2008).There is more production of reactive oxygen species 
(ROS) due to activation of xanthine oxidase and related oxidative mechanisms. The 
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hydroxyl radicals produced as a result of dissociation of the ROS result in higher damage 
to cell membranes and cellular structure during reperfusion injury. So far, there is no 
known clinical intervention to prevent or reverse the damage caused by reperfusion injury 
(Sanada, Komuro, & Kitakaze, 2011). However, a promising strategy is to exploit the 
inherent cardio protective properties of the myocardium by conditioning it to become 
more tolerant to I/R injury, a property known as ischemic preconditioning (IPC). 
IPC is a type of conditioning stimulus applied before, during, or after a sustained 
ischemic episode. The conditioning stimulus can also be applied remotely of the target 
organ to protect it against I/R injury, referred to as remote preconditioning. In this respect, 
subjecting a distant organ to brief sublethal bouts of ischemia followed by brief reperfusion 
protects the target organ against I/R injury. Experimental models have shown that 
preconditioning can protect many organs from the damage caused by I/R injury including 
the heart, kidney, brain, lungs and skeletal muscles (Zhou et al., 2007). One of the main 
mechanisms by which IPC is protective involves its capacity to prevent reductions in the 
blood flow that accompanies endothelial and myocardial I/R damage. 
Exercise economy is an important component that plays a central role in 
endurance exercise performance. An economical athlete will consume less oxygen for a 
given steady-state submaximal exercise workload than a less economical athlete, and as a 
result, will show significant performance benefits, particularly at long distance events by 
expending less energy. Improvements in exercise economy following IPC may contribute, 
in part, to enhanced exercise performance. Recently it was shown that IPC prevents 
reduction in blood flow after strenuous exercise and improves swimming, cycling and 
running performance (Bailey et al., 2012; De Groot et al. 2010; Clevidence et al. 2012; 
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Crisafulli et al., 2011). The reason to explain these performance benefits with IPC are not 
fully understood. Moreover, to date, there is little scientific insight into whether remote 
IPC improves exercise economy. 
 
1.1 : STATEMENT OF PROBLEM 
 
Little is known about the effect of remote IPC on exercise performance and a limited 
number of studies have been published. Moreover, the effect of remote IPC on running 
economy has not been investigated so far to our knowledge. In the light of previous research 
it is important to determine the potential beneficial effects of remote IPC on running 
economy. 
 
1.2 : SPECIFIC AIM 
Specific Aim: To determine the effects of remote IPC on runningeconomy. 
 
Hypothesis: We hypothesize that remote IPC will improve runningeconomy. 
 
 
1.3 : DEFINITION OF TERMS 
 
Ischemia-Reperfusion Injury: Cellular injury caused by the rapid restoration of blood flow 
following a sustained period of ischemia. 
Ischemic Preconditioning: Ischemic preconditioning is a technique which protects the 
heart against reperfusion injury by exposing the heart to nonlethal intermittent periods of 
ischemic bouts prior to prolonged ischemia. 
 
 
Remote Ischemic Preconditioning: Remote ischemic preconditioning refers to application 
of small ischemic bouts at regular interval which when applied to one organ confers 
preconditioning against reperfusion injury to a distant organ. 
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Exercise Economy: The amount of energy (oxygen consumed) to run at particular 
velocity. 
 
 
Experimental Design 
 
Randomized, single-blind cross-over study 
 
 
1.4 : INDEPENDENT VARIABLE 
 
Remote ischemic preconditioning versus sham 
 
 
1.5 : DEPENDENT VARIABLES 
 
Running economy, oxygen consumption 
 
Respiratory exchange ratio, submaximal heart rate, minute ventilation 
 
 
 
1.6 : ASSUMPTIONS 
 
1. All participants completed medical history questionnaire accurately. 
 
2. All participants followed the protocols as guided. 
 
3. Equipment was working properly. 
 
 
1.7 : DELIMITATIONS 
 
1. Healthy, recreationally active adult men and women from Brookings, Count 
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2: LITERATURE REVIEW 
 
 
2.1 : OVERVIEW 
 
Myocardial I/R injury occurs when cardiac myocytes and coronary endothelial cells 
are exposed to ischemia that is followed by reestablishment of blood flow (Kloner & 
Jennings, 2001). The myocytes undergo reversible damage without any permanent 
damage or cell death if the blood supply is restored within 15 minutes. If the duration and 
severity of ischemia is of a longer duration, it causes greater reperfusion pathologies 
which can then lead to reperfusion injury (Kloner & Jennings, 2001; Kloner & Rezkalla, 
2006). Reperfusion injury involves a group of local and systemic inflammatory responses 
that can result in widespread vascular endothelial dysfunction and cellular manifestation 
characterized by myocardial stunning, endothelial injury and irreversible cell damage and 
necrosis (Verma et al., 2002). Cellular damage following I/R injury can be alleviated by 
IPC, a protective phenomenon that has undergone extensive scientific study aimed at 
reducing myocardial dysfunction following coronary revascularization and myocardial 
infarction. Recently, while it is clear that reperfusion injury affects all organs and tissues 
exposed to sustained ischemia, studies have shown that I/R injury also diminishes 
endothelial function in systemic arteries that supply blood to skeletal muscle. Endothelial 
dysfunction caused by I/R injury can also be prevented by IPC and studies have provided 
evidence to indicate that IPC can improve exercise performance by enhancing maximal 
oxygen consumption, lactate metabolism, and perhaps exercise economy (Bailey et al., 
2012; De Groot et al., 2010). Accordingly, the following literature review will discuss the 
cellular mechanisms that contribute to I/R injury and the factors by which remote IPC 
protects against it. In addition, a review of studies thathave shown favorable benefits of 
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IPC to improve exercise performance will be discussed. 
 
2.2 : ISCHEMIA-REPERFUSION INJURY 
 
Reperfusion injury following ischemia initiates an inflammatory response in the 
endothelium causing vasoconstriction, platelet and leukocyte activation, increase radical 
oxygen species and increased exudation (i.e., leakage) of protein-rich plasma out of the 
vessels (Hausenloy & Yellon, 2008). The inflammatory response can become generalized 
and effect multiple organs leading to systemic inflammatory response syndrome or the 
multiple organ dysfunction syndrome (Eltzschig & Collard, 2004). Severe microvascular 
dysfunction can lead to ‘no-reflow’ phenomenon where blood flow does not return during 
reperfusion. Ischemia negatively impacts multiple cellular metabolic pathways and brings 
about structural changes (Agati, 1999; Granger, 1999). Prolonged ischemia inevitably 
causes tissue necrosis. In this respect, there is a reduction incellular oxidative 
phosphorylation that causes depletion in ATP and phosphocreatine levels. ATP depletion 
results in altered membrane function because the membrane is driven by ATP- dependent 
ionic pumps 2. In all cells, particularly the cardiac myocytes and endothelium, I/R leads 
to increased oxidative stress, calcium imbalances, expression of pro inflammatory 
cytokines, and endothelial impairments in blood flow and fibrinolytic capacity (Tapuria 
et al., 2008). These factors will be discussed below in greater detail. 
 
Oxidative Stress 
 
Generation of toxic levels of ROS plays an important role in the pathogenesis of 
reperfusion injury. Reactive oxygen species such as a) superoxide anion (O2-), b) 
hydroxyl radicals (OH-), c) hypocholorous acid (HOCl), d) hydrogen peroxide H202, and 
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e) peroxynitrite, a derivative of nitric oxide are produced during reperfusion (Kaminski et 
al., 2002) During reperfusion there is an excessive accumulation of hypoxanthine by 
xanthine oxidase that leads to the formation of ROS. ROS are also produced from 
cytochrome oxidase, and cyclooxygenase, and the oxidation of catecholamines. ROS 
cause lipid peroxidation and injury to cellular membranes (Eltzschig & Collard, 2004). 
 
Cellular Calcium Overload 
 
Imbalance in calcium homeostasis plays an important role in the development of 
reperfusion injury. Excessive amount of calcium enters the sarcolemma through L-type 
calcium channels located in cardiac muscle as well as skeletal muscles. The sensitivity of 
myofilaments is also distorted (Gross et al., 1999). There is a reduction in the production 
of ATP due to unavailability of oxygen during ischemia (Gross et al., 1999). Heart shifts 
to anaerobic metabolism for energy production which leads to increased lactate 
concentration resulting in decreased pH of the myocytes. Low levelsof ATP also interfere 
with sodium/potassium ATPase pump (Na/K ATPase) causing greater influx of sodium 
(Na) inside the myocytes (Verma et al., 2002). Reduction in pH activates the sodium ion 
hydrogen exchanger to maintain the acidic environment of the cells. Sodium ion 
hydrogen exchanger maintains the increase in intracellular level of Na by efflux of Na 
and influx of Ca ion (Verma et al., 2002). To maintain the osmolality, Na is pushed out of 
the cell in exchange for calcium that leads to Ca2+overload in the cell. The excessive Ca 
in the myocyte goes into the sarcoplasmic reticulum, leading to overload of calcium in 
sarcoplasm which is again pushed out of the cell. A vicious cycle of calcium uptake and 
release results in excessive use of ATP and imbalance in Ca homeostasis (Hoffman, 
Gilbert, Poston, & Silldorff, 2004). The process leads to permanent damage of these 
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pumps during ischemia (Hoffman et al., 2004). The build-up of calcium inside the cells 
lead to hypercontracture of cardiac myocytes, that ultimately results in contraction band 
necrosis which signifies damage to sarcolemma and cell death during reperfusion. 
Hypercontracture in one myocyte can affect the neighboring myocyte (Hoffman et al., 
2004). The uninjured neighbor myocyte is also exposed to excessive calcium through the 
gap junctions that can lead to calcium overload in the cell. The hypercontraction occurring 
in the adjacent myocyte can also cause mechanical disruption in the unexposed myocyte 
through intercalated disks (Hausenloy & Yellon, 2008). Collectively, calcium overload in 
cardiac myocytes is thought to be a primary reason contributing to I/R injury. 
 
Inflammation 
 
I/R injury increase the expression of certain enzymes and genes that result in 
inflammation. In a study done by Zager et al. (2009), it was observed that renal ischemia 
leads to a variation of histone at proinflammatory genes and upregulation of histone 
modifying enzymes (Set1, BRG1) expression. The study established an associated 
increase in cognate mRNA and cytokine levels of these genes, which has a relevance to 
the mechanism of injury after a period of ischemia (Zager & Johnson, 2009). 
 
 
Endothelial Dysfunction 
 
Reperfusion leads to severe intravascular inflammation and severe endothelial 
dysfunction. There is a rise in production of the vasoconstrictor endothelin-1 and 
increased ROS that results in increased vasoconstriction and reduced blood flow. The 
endothelial dysfunction also disturbs the balance between coagulation and anti- 
coagulation factors in the blood. Polymorphonuclear neutrophils are transported to the 
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intravascular space from the interstitial space during ischemia, and such responses may 
contribute significantly to tissue damage during subsequent reperfusion (Granger, 1999; 
Jordan et al., 1999). Moreover, Kharbanda and colleagues (2009) were one of first to show 
that 20 minutes of forearm ischemia impaired endothelium-mediated vasodilation 
(Kharbanda et al., 2009). In 14 healthy men, blood flow responses to acetylcholine were 
blunted by ~50% following endothelial I/R injury. Interestingly, subjecting one forearm 
to remote IPC protected the arm exposed to sustained ischemia against reperfusion injury. 
In another study conducted by Bailey et al. (2012), remote IPC prevented the reduction in 
endothelial-mediated vasodilator function of the brachial artery after vigorous lower limb 
exercise. Thirteen men performed treadmill running followed by a remote IPC protocol. 
While acute bouts of strenuous exercise has been shown to blunt vasodilation, this study 
showed that remote IPC was able to prevent it 3. Furthermore, an experimental study 
done Pedersen and colleagues showed that endothelial ischemia-reperfusion injury 
significantly diminishes tissue-type plasminogen activator (t-PA) release, a well- 
established marker of vascular endothelial health and function, in health men. 
Surprisingly, IPC could not prevent the reduction in t-PA release in this study. Twenty-two 
men underwent local IPC, remote IPC and a sham protocol of the forearm following I/R 
injury caused by suprasystolic upper arm cuff inflation (~220 mmHg for 15 min). Similar 
to the t-PA response, the investigators observed impaired vasodilation due to infusion of 
substance P and acetylcholine that was not prevented by remote or local IPC (Pedersen et 
al., 2012). 
 
2.3 : CLINICAL FEATURES OF REPERFUSION INJURY 
 
In the clinical arena, I/R injury contributes to post-operative early mortality, 
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recurrent myocardial infarction, organ failure, and more extensive cell damage. However, 
while early restoration of blood flow is required to salvage cells and improve patient 
survival undergoing surgical procedures, such as percutaneous coronary intervention, 
reperfusion itself accelerates damage, undermining the effectiveness of prompt 
reperfusion therapy to restore organ function. Indeed, I/R injury was an underlying feature 
responsible for early death following coronary artery bypass graft surgery (Weman et al. 
2000), despite early and successful reperfusion. In addition, it contributes to adverse 
outcomes in recipients of organ transplants and in patients undergoing organ resection 
(i.e., surgical removal of segments of organs), and contributes to organ rejection following 
successful transplantation (Huang et al. 2009). The clinical features of these adverse 
changes following I/R injury are characterized by myocardial stunning, reperfusion 
arrhythmias, and multi-organ dysfunction syndrome. 
 
Myocardial stunning 
 
The term myocardial stunning was first described by Heyndrickx et al. in 1975. It 
is defined as “prolonged post-ischemic dysfunction of viable tissue salvaged by 
reperfusion” (Kloner & Jennings, 2001). During myocardial stunning the myocardial 
cells undergo prolonged I/R which is reversible with time. Typically, myocardial 
stunning caused by I/R injury leads to impaired ventricular contraction that can last for 1- 
3 days after an ischemic event (Bolli & Marbán, 1999). The mechanism of myocardial 
dysfunction includes reduction in ATP synthesis, vascular spasm, intracellular calcium 
reuptake and increase in ROS (Eltzschig & Collard, 2004). In fact, such brief periods of 
ischemia are encountered in the clinical situations of angina, coronary vasospasm, and 
balloon angioplasty, and mostly are not associated with coupled myocyte cell death. 
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Myocardial stunning is one of the causative factor of cardiomyopathy that in time can lead 
to cardiac failure (Verma et al., 2002). 
 
Reperfusion arrhythmias 
 
Arrhythmias, ventricular tachycardia, atrial fibrillation and accelerated 
idioventricular rhythms are common in patients undergoing cardiac surgeries such as 
coronary artery bypass graft, coronary angioplasty and open heart surgeries involving 
valvular replacement. Arrhythmias frequently occur in cardiac patients following 
reperfusion. Reperfusion arrhythmias, which represent the first stage of myocardial I/R 
injury following 1-5 minutes of sustained ischemia, occur due to abrupt changes in the 
ionic concentrations. Increasing the blood flow in gradually, in stages reduces the 
incidence of such arrhythmias and reducing the risk of postoperative mortality (Eltzschig 
& Collard, 2004). 
 
Multi-organ dysfunction syndrome 
 
Multiple-organ dysfunction syndromes (MODs) are the extreme outcome of I/R 
injuries. MODs occurs due to the failure of coagulation and immune system leading to 
clotting, disseminated intravascular coagulation and compromised immune system. 
Respiratory failure, which is often followed by acute respiratory insufficiency, ensues 
within 27-72 hours of initial ischemic event (Kaminski et al., 2002). Liver, kidney, 
gastrointestinal, myocardial and central nervous system deficits follow respiratory failure. 
MODs account for up to 30–40% of intensive care unit mortality (Granger, 1999). 
In summary, I/R injury can prove fatal, if goes unchecked. In clinical settings 
anti- inflammatory drug therapies are used in postoperative conditions to control 
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exaggerated inflammatory response. However, a promising strategy to prevent or reduce 
the adverse clinical consequences of I/R injury is to precondition the cells to become 
more tolerant against a sustained ischemic bout. The following section will detail the 
mechanisms of preconditioning and its capacity to reduce injury during clinical situations 
and improve exercise performance. 
 
2.3 : ISCHEMIC PRECONDITIONING 
 
In an early experiment, Murry et al. (1986) showed a reduction in myocardial 
infarct size in canine hearts after the application of a preconditioning stimulus via 
occlusion of the circumflex coronary artery (Murry et al. 1986). As a result of this 
groundbreaking study, the concept of ischemic preconditioning was introduced by these 
authors in 1986. In this experiment, the circumflex coronary artery was exposed to four 5 
min occlusions, each separated by 5 min of reperfusion, which was then followed by 
continuous ischemia for 40 minutes. They observed a 25% reduction in the myocardial 
infarct size with the IPC stimulus (Murry et al., 1986). This study laid the groundwork for 
many subsequent studies showing the protective benefits of preconditioning a tissue 
locally and remotely. 
IPC is an intervention that aims at improving ischemic tolerance of the tissues prior to the 
actual ischemic insult. Small, intermittent bouts of ischemia and reperfusion provide the 
target organ a level of resistance against I/R injury. IPC can be applied directly or 
indirectly to the target organ. The direct (also known as local) form of IPC is not widely 
practiced clinically because the target organ has to be exposed to the preconditioning 
stimulus through surgical intervention or through the occlusion of major blood vessels 
which can cause trauma to the vessels and prove detrimental. On the other hand, remote 
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IPC was first demonstrated by Pryklenk et al. in 1993 in which they showed that small 
episodes of ischemia in one vascular bed protected a different area of the myocardium in 
the canine to sustained coronary artery occlusion. These investigators suggested that 
preconditioning was mediated by some unknown factors that were released and 
transported from the preconditioned area to the tissue experiencing I/R injury (Przyklenk 
et al., 1993). An experiment done by McClanahan et al. also in 1993, showed a reduction 
in myocardial infarct size in the rabbit when a preconditioning stimulus was applied to 
the kidneys. (McClanahan et al. 1993). In this manner, remote IPC was used for inducing 
protection of a distant organ through a peripheral limb or internal organ. In another 
studydone by Birnbaum et al. (1997), cardioprotection against I/R injury was triggered 
via lower limb skeletal muscle IPC. Indeed, they showed that occluding blood flow in the 
gastrocnemius muscle resulted in a reduction of myocardial infarct size by 65% in rabbit 
heart (Birnbaum et al. 1997). Similarly, Oxman et al. (1997) demonstrated that 
application of remote IPC to the hind limb of rats using a tourniquet prevented 
reperfusion arrhythmias (Oxman et al., 1997). 
The protection through IPC occurs in two phases. An early window and a late 
window of protection. The early window of protection wanes after a few hours but it is the 
most potent against IR injury. The late window of protection then recurs after 24-48 hours 
and can persist up to 72- 96 hour (Kharbanda et al., 2009). The mechanism of action in 
early and late window of protection share common features but there are inherent 
differences. Generally, IPC acts through three basic biological processes; application of 
ischemic stimulus, the communication of the IPC stimulus via neuronal pathways and 
blood borne humoral pathways and then induction of the protective effect on the vital 
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organs such as heart (Baxter & Ferdinandy, 2001), The proposed mechanism is thought 
to involve the release of adenosine, bradykinin and opioids that bind to target cells 
exposed to IR injury. The exact mechanism by which the remote IPC stimulus is 
transmitted to the target organs however not clear, as transmission can be through multiple 
pathways and requires a combination of humoral, neuronal or systemic mechanism 
(Przyklenk et al., 1993). Nevertheless, remote IPC has been researched for its potential to 
reduce the harmful effects of reperfusion injury and protection against myocardial 
infarction, particularly in the clinical arena. It has been seen that remote IPC stimulus 
improves cutaneous circulation remarkably (Shimizu et al. 2007). The study done by 
Kharbanda et al. (2009) demonstrated a normal ventricular function and reduction in 
myocardial infarct size after prolonged ischemia preceded by remote IPC in animal 
models. The same study also showed that remote IPC prevented reperfusion induced 
endothelialdamage (Kharbanda et al., 2009). The application of an IPC preconditioning 
stimulus also causes an improvement in the blood flow to the heart and improves left 
ventricular function (Zhou et al., 2007). Many studies have found profound benefit of 
remote IPC for improving clinical outcomes followed by a cardiac surgery. For example, 
Hausenloy et al. (2007) found that remote IPC mediated by limb ischemia lowered the 
concentration of cardiac troponin-T release after surgery. Elevated cardiac troponin-T 
levels during surgery are believed to be associated with poor health consequences after 
the surgery (Luca et al., 2013). A long- term follow up study done by Davies et al. 
(2013), which was designed to determine the long-term benefits of RIPC after 
percutaneous coronary intervention, demonstrated that remote IPC is associated with 
reduced levels of troponin-I 6 months after the surgery. Reduction in levels of troponin I 
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were associated with reduced mortality due to cerebral and cardiac causes in the 6 year 
follow-up (Davies et al., 2013). Despite these clear clinical benefits of remote IPC to 
reduce cellular injury, it has not been translated into widespread clinical practice. The 
precise mechanisms to explain the cellular protection afforded by IPC, particularly how 
remote IPC induces protection of a distant organ have been extensively studied. Many 
studies were done to understand how the IPC stimulus travels from the effector to the 
target organ. The following section will exclusively focus on the mechanisms thought to 
be responsible for the favorable effects of remote IPC to protect against I/R injury. 
 
 
2.4 : MECHANISMS TO EXPLAIN REMOTE IPC 
 
Lim and colleagues (2010) suggested possible involvement of neuronal and 
humoral pathways to conduct the remote IPC stimulus. To test this notion, remote IPC 
was applied by 3X5 min left femoral artery occlusion each followed by 5 min reperfusion 
before prolonged myocardial ischemia in absence and presence of femoral vein occlusion 
(humoral pathway) and femoral nerve resection and/or sciatic nerve resection (neural 
pathway) in C57BL/6 mice. Remote IPC protected the heart from myocardial damage 
during sustained ischemia-reperfusion injury. Interestingly, the study concluded 
contribution from both humoral and neuronal pathways in translation of remote IPC 
stimulus because much of the protection was abolished when the femoral vein was 
occluded and the femoral/sciatic nerve were resected. This study suggests complex and 
redundant mechanisms that involve the release of substances from the preconditioned 
tissue that are transported to the target organ to induce protection. It also shows that some 
of the signal for protection is mediated by the nervous system (4. 
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With respect to potential humoral factors, it is thought that this mechanism is responsible 
for the initial phase of protection because these factors appear to be released immediately 
into the blood stream following preconditioning. This was shown in a study by Dickson 
et al. (1999) in which they obtained blood from a preconditioned rabbits that was 
transfused into unconditioned rabbits that were subjected to myocardial I/R injury. Rabbits 
that received preconditioned blood demonstrated a reduction in myocardial infarct size by 
77%. The proposed mechanism of action suggested by the study was through opioids. 
(Dickson et al., 1999). Another study by Dickson and colleagues (1999) in which 
coronary effluent of preconditioned rabbit’s hearts was transferred to rabbits that were 
subjected to myocardial I/R injury. Transfer of the coronary effluent significantly reduced 
myocardial infarction size compared to rabbits that did not receive the effluent, 
suggesting a humoral mechanism (Dickson et al., 1999). A study done by Weinbrenner et 
al. (2002) demonstrated cardioprotection through infrarenal occlusion of aorta in rats. 
Their findings point to a protein kinase-dependent humoral mechanisms contributing to 
remote IPC (Weinbrenner et al. 2002). Several other mechanisms that are thought to be 
responsible in the translation of remote IPC stimulus from the effector organ to the target 
organ have also been studied. A summary of some of these factors follows. 
 
 
Opioids. Opioid receptors are present in the neuromuscular junction of heart, skeletal 
muscles and intestinal tissues (Tapuria et al., 2008). Three identified subgroups of opioid 
receptors - mu, kappa and delta - are known to play a role in the conduction of 
preconditioning. All these receptors were identified in the myocardium of rat and 
participate in the conduction of preconditioning stimulus. Administration of Nalaxone, 
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which is a nonspecific opioid receptor antagonist, abolishes the cardioprotection induced 
by remote IPC of mesenteric artery occlusion, thus infers the involvement of opioid 
receptors in for inducing cardioprotection (Zhang et al., 2006).  Preconditioning induced 
by opioids works by reducing depletion of ATP, reducing the accumulation of lactate, 
and reducing the recruitment and infiltration of neutrophils and myeloperoxidase activity 
in preconditioned skeletal muscles. The attenuation in lactate accumulation during early 
reperfusion is triggered by activation of opioid receptors (Tapuria et al., 2008). Opioids act 
via G-protein coupled receptor activation of multiple kinases and modulation of 
mitochondrial and sarcolemmal potassium ATP channels serving as final end-effector. 
Some studies point towards the involvement of delta and kappa-opioid receptors in 
remote IPC (Zhang et al., 2006). Weinbrenner et al. (2004) reported that cardioprotection 
may act via delat-1-opioid receptors (Weinbrenner et al. 2004). In the study done by 
Zhang et al. (2006), opioid receptor agonist U-50,488H was introduced in blood of mice 
which mimicked the effect of RIPC induced by femoral occlusion. The cardioprotective 
effect was absent when opioid receptor antagonist binaltrophimine was introduced 
(Zhang et al., 2006). 
 
 
Nitric oxide: Nitric oxide is produced from the metabolism of L-arginine by the enzyme 
nitric oxide synthase (NOS). There are three isoforms of NOS, endogenous NOS, 
neuronal NOS and inducible NOS. Inducible NOS is produced only in response to 
inflammation in the hepatocytes, endothelial cells, Kupffer cells, neutrophils and T- 
lymphocytes (Abu-Amara et al. 2011). Endogenous NOS has protective effect on 
ndothelium and is constantly produced in small quantities, which protects the 
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endothelium. A study done by Abu Amara and colleagues investigated the role of 
endothelium nitric oxide in inducing remote IPC in mice models. Mice with muted 
expression of endothelium nitric oxide synthase suffered greater hepatic injury as 
compared to the wild mice due to reperfusion after ischemia (Abu-Amara et al., 2011). 
Consequently, mice with an overexpression of endothelium nitric oxide synthase showed 
resistance to hepatic reperfusion injury (Duranski et al., 2006). To add to it, a study done 
by Tukono et al. (2008) established that induced NOS acts as a trigger in maintaining 
remote IPC response rather than a mediator of remote IPC. The study observed deficient 
preconditioning response due to lack of induced NOS gene in mice. As suggested by 
some other studies, ROS, cytokines, and NO are generated in venous effluents following 
intestinal ischemia reperfusion (Tapuria et al., 2008). Collectively, nitric oxide plays a 
key role underlying many of the protective effects of remote IPC. Nitric oxide protects the 
microvasculature through vasodilatation, inhibition of neutrophil aggregation, inhibition of 
stellate cell activation, and by activating cyclic GMP in myocardium and inhibition of 
cyclic GMP levels and reducing energy demand. It appears that NO also works by 
activation of PKC, NF-k B and increased transcription of induced NOS in the later phases 
of remote IPC. 
 
 
Bradykinin: Bradykinin acts through humoral and neuronal pathways to confer remote 
IPC to a target organ. Studies by Shoemaker and colleagues showed that intermittent 
occlusion of the mesenteric artery induced cardioprotection that was mediated by 
bradykinin (Schoemaker & van Heijningen, 2000). Bradykinin activates efferent nerves 
which stimulate bradykinin receptor-2 on heart which in turn induces cardioprotection. 
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Wolfrum et al. (2001) demonstrated that bradykinin activates PKC. The mechanism of 
action through KATP channels is proposed but not clearly understood. 
 
 
Adenosine: Adenosine is a purine nucleoside composed of adenine attached to ribose 
base. It is molecule present in human tissues that can initiate an IPC response as well as 
can act a as a mediator for remote IPC. Adenosine is produced in muscle cells and 
endothelial cells. The production of adenosine can increase up to 50 times during 
ischemic period by the breakdown of ATP (Pell et al., 1998). After the breakdown of 
ATP, adenosine then diffuses to the interstitial space and reaches the blood stream. The 
half-life period of adenosine id 0.6-1.5 s and is readily taken up by endothelial cells, RBCs 
and pericytes which help in metabolizing adenosine. Therefore, it is suggested that 
adenosine cannot reach the target organ through circulation (Pell et al., 1998). Some 
studies suggested a neuronal mode of action of adenosine in which it stimulates the 
afferent nerves locally in the mesenteric bed, which then stimulate adenosine receptors 
present in the ventricular cardiomyocytes and endothelial cells (Bulbulian et al. 1986). 
Renal preconditioning induced by renal artery occlusion reduced myocardial infarct size 
by 65%; however, the preconditioning response was ineffective when nonselective 
adenosine receptor antagonist 8-SPT or the KATP channel blocker 5-HD was infused 
before renal preconditioning (Pell et al., 1998). Adenosine may act through adenosine 
receptors present in the kidneys that release more substances including endothelin, 
prostaglandin and renal medullary lipids that can provide cardioprotection through K- 
ATP channels. A study by Pang and colleagues (1997) established a role of adenosine in 
remote IPC. Adenosine blockade using 8-SPT and free radical scavenger 
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mercaptopropionyl glycine (MPG) aborted the protection induced by remote IPC. The 
study also found that on infusion of reserpine the levels of adenosine dropped and 
beneficial effects of remote IPC were abolished. The study done by Pell et al. (1998) on 
rabbit models also showed that blockade of adenosine before induction of remote IPC 
prevented cardioprotection. Taken together, several experimental animal models have 
provide clear evidence of the favorable effects of adenosine to mediate IPC. 
 
 
Potassium ATP channels (KATP): KATP channels are present in brain, smooth 
muscles, skeletal muscles, intestine, kidney and pancreas. KATP channels play an 
important role in protecting the heart against hypoxic and ischemic stress 5. KATP 
channels are present in the sarcolemma as well as in the mitochondria of the cells. Moses et 
al. demonstrated that administration of nonselective blocker glibenclamide and selective 
calcium channel blockers 5HD abolished the protective effect of remote IPC, showing the 
involvement of sarcolemma KATP channels 5. KATP channels act by reducing depletion 
of ATP and maintaining phosphocreatine levels and intracellular acidic balance inside the 
cardiac myocytes after remote IPC 6. The KATP channels also act by reducing the 
hydrolysis of ATP and mitochondrial ATPase activity, thus sparing ATP breakdown. 
Opening of KATP channels preserves calcium balance inside the mitochondria thereby 
maintaining the electron transfer between mitochondria and ATPase enzymes (Moses et 
al., 2005; Fairbanks & Brambrink, 2010). Collectively, many studies are underway to 
determine the mechanisms underlying the cellular protection conferred by IPC against 
I/R injury. Moreover, several clinical trials are currently underway to translate these 
protective benefits to reduce myocardial I/R injury by subjecting a patient to short 
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periods of limb ischemia immediately before a surgical procedure. Recently however, a 
new area of research has provided preliminary evidence showing that IPC also has 
important benefits on exercise performance, which may be mediated by mimicking some 
of the protection induced by exercise preconditioning, a phenomenon that shares some 
mechanisms as IPC. Indeed, remote IPC has been shown to improve performance in sports 
such as running, swimming and cycling. It may be that part of the benefits of IPC on 
exercise performance is mediated by changes in exercise economy. 
 
 
2.4 : EXERCISE ECONOMY 
 
A person with a better exercise economy will be able to perform at a higher level 
compared with a person with lower exercise economy even if other factors such as 
maximal oxygen consumption and lactate threshold are similar. The economy of motion 
relates to the quantity of oxygen (ml/kg/min) required to move at a given speed or 
generate a specific amount of power. Exercise economy has been shown to be an 
important predictor of endurance exercise performance in a number of endurancesports 
(cycling, swimming, running etc.) and can help to explain differences in performance 
between individuals. With respect to running economy, differences are determined by 
various factors such as biomechanical factors joint stability, stride length anthropometrics, 
kinetics and kinematics and other training factors (Saunders et al. 2004). 
 
 
 
2.5 : FACTORS AFFECTING RUNNING ECONOMY 
 
I. Biomechanical Factors. Several muscles and joints of the body coordinate for the 
production of movement at a required energy cost. Altering the mechanics of joint stability 
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and differences in muscle stiffness can either increase or reduce the energy cost of 
submaximal exercise. Muscle stiffness has shown to increase power production during 
bench press. Studies have also shown that strength and power interventions can improve 
exercise economy and performance by increasing the stiffness of muscles and tendons 
(Dumke et al., 2010). Kyrolainen et al. (2003) indicated a relationship between myosin 
heavy chains and titin isoforms in trained runners, which can have an effect on muscle 
stiffness. 
A. Flexibility: With respect to running economy, research has established that 
it can be improved by improving joint stability and reducing flexibility of the hip and calf 
regions (Craib et al., 1996).To support the literature further, it has been shown that orthotic 
use improves running economy at low intensity by reducing excessive foot pronation and 
improving stability of the joints (Burke & Papuga, 2012). Interestingly, it is recognized 
that sit-and-reach range of motion is negatively associated with running economy (Brown 
et al., 2011. Indeed, flexibility accounts for 46% of variability in the running economy. A 
study done by Godges and colleagues (1989) showed that running economy was 
improved in college athletes by improving the flexibility of the hip flexors and extensors. 
The authors noted that pelvic balance, improved hip flexibility and myofascial balance 
are important for neuromuscular balance and contraction to improve running economy. 
In contrast the study done by Gleim et al. (1990) showed that runners with least flexible 
muscle at the trunk and pelvic regions had better running economy as the metabolic 
demand was lowered due to reduced ROM and more stability. In a similar study Creib et 
al. (1996) reported that lower flexibility in the lower limb especially hip and calf muscles 
was associated with a better running economy. Improved running economy is dependent 
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on greater stability of the pelvic muscles and lower need of energy expenditure during the 
foot strike and more storage of elastic energy in the lower extremities. Other important 
biomechanical factors affecting running economy per se include stride length, 
anthropometrics, and kinematics. 
B. Stride length: Trained athletes are known to have longer stride lengths and 
more efficient exercise economy during running. However, studies have shown that 
training could not improve stride length and running economy over a period of 7 months 
in novice athletes. Williams and Cavangh (1987) also showed the impact of other 
biomechanical factors that affect stride performance with running economy. They 
concluded that most economical runners possessed lower force peak at heel strike, greater 
shank angle, smaller maximum plantar flexion angle after toe off and greater forward 
trunk lean and lower minimum velocity of a point on knee during foot contact. 
C. Anthropometrics: Body weight, height, body fat, and leg length have a critical 
impact on the running economy. There is a metabolic cost of running associated with the 
limbs due to their specific angular inertia. A large variation was seen in athletes with 
similar segmental length and mass. The authors reported an inverse relationship between 
body mass and maximal oxygen consumption (r = –0.52) and between thigh 
circumference and submaximal oxygen consumption (r = –0.58) concluding that the 
runners with higher mass have a better running economy. 
D. Kinetics and Kinematics: Studies have indicated that running economy is better 
if the athlete runs at a self-selected stride length compared to a predetermined stride 
length (Saunders, et al. 2004b). Others concluded that runners tend to choose an optimal 
stride length and rate with a certain amount of training period for a better running 
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economy (Williams & Cavanagh, 1987). It has also been proposed that runners tend to 
adjust their stride length and number according to therate of their perceived exertion for 
an efficient running economy. Better running economy was also associated with more 
extended leg during foot strike with longer foot contact time and lower elevation in the 
vertical peak force. More horizontal heel velocity and greater maximal plantar flexion 
velocity, lesser arm movements during running was contributor towards running 
economy (Saunders et al., 2004a). 
II. Training 
 
A. Strength training: Improving muscle strength improves running economy by 
improving muscle coordination, changing motor unit recruitment patterns and conserving 
elasticity by improving neuromuscular function (Hunter et al., 2011). Strength training 
can improve the variables associated with running economy such as short contact times 
and faster forces. Some studies have also demonstrated that resistance training improves 
endurance in athletes (Bulbulian et al., 1986). A combination of both resistance and 
endurance training has improved both performance and running economy in athletes. A 
specific type of strength training called as plyometrics has proven to be beneficial for 
improving running economy (Turner et al. 2003). Plyometrics cause neural adaptation by 
increasing the recruitment of motor units without causing muscle fiber hypertrophy. 
Plyometrics increase tone and stiffness of the muscles and tendons which helps utilize and 
store elastic energy more efficiently 7. Paavolainen and colleagues (1999) demonstrated 
that 9 months of high-intensity strength training can improve running economy by 8% 
and exercise performance by 3% with no difference in VO2 max with training in 
moderately trained individuals as a result of improved neuromuscular function. 
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B. Altitude training: Research indicates that altitude training can improve running 
economy in sea level runners (Turner et al., 2003). The mechanism can be attributed to 
increases in hemoglobin levels and oxygen carrying capacity. Weston et al. showed that 
Kenyan runners who trained at altitude were more resistant to fatigue than Caucasian 
runners who trained at sea levels despite running at the same treadmill running velocity 
and similar maximal fitness levels. One mechanism thought to contribute to the improved 
running performance was reduced lactate production and higher level of oxidative 
enzymes in Kenyan athletes 8. 
While there are a variety of factors and training methods that can improve exercise 
performance by favorably modifying economy of movement, recent data also points to 
good potential of IPC to induce exercise benefits. However, to date, no study has directly 
determined the impact of IPC on exercise economy. 
 
2.5 : ISCHEMIC PRECONDITIONING AND EXERCISE PERFORMANCE 
 
One of the first studies to show benefits of IPC on exercise performance was 
conducted by De Groot et al. in 2010. They studied the effect of local leg IPC on maximal 
oxygen uptake in 15 healthy male and female cyclists. The subjects were made to perform 
incremental maximal exercise test on cycle ergometer on two separate appointments 
which were a week apart. The exercise protocol, which consisted of an initial cycling 
power output of 50W sustained for 4 min followed by progression to 100W for 4 min and 
then 150W for 4 min until exhaustion, was counterbalanced with one day of IPC followed 
by the maximal exercise test and a control trial (without IPC). Following the IPC trial, the 
cyclists showed a significant improvement in maximal oxygen uptake by 3%. The maximal 
oxygen consumption with was 58.4 ml/kg/min with IPC compared with 56.8 ml/kg/min 
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without it. The maximal power output was also increased (~2%) significantly (from 
366W during control to 372W with IPC). Whereas during submaximal testing there was 
no significant differences in oxygen consumption, respiratory exchange ratio, heart rate 
or power output. 9. The authors indicated that a factor contributing to improvement in 
performance after IPC was due to improvement in the blood flow to the muscles, possibly 
via KATP channels, adenosine, or nitric oxide, which are thought to be central to the 
vascular benefits of IPC. This study mainly focused on the effect of early phase of IPC on 
maximal performance as the participants were made to do the maximal cycle ergometer 
test 5 min after the application of IPC. However, more studies are needed to investigate the 
mechanism related to change in vascular adaptations after the application of remote IPC 
and to ascertain the impact of the late window of protection 9. Jean et al. in 2011 showed 
that remote IPC improved maximal exercise performance in highly trained swimmers. 
Twenty-seven professional swimmers were included in the study, 16 of them completed 
two submaximal swimming protocols and 18 completed two maximal swim trials 
consisting of a 100 m swim. Using a randomized crossover study, each subject (within 
either the submaximal or maximal trials) completed four, 5 min bouts of sublethal 
ischemia of the upper arm each followed by 4X5 min reperfusions. The remote IPC 
protocol significantly reduced the time to complete a maximal 100 m swim (an average 
of 7 sec reduction). There were no differences in submaximal exercise performance with 
the remote IPC trial. The reason behind no improvement in the submaximal performance 
is not well understood, however it may be due to different cellular response to remote 
IPC during maximal and submaximal trials. Submaximal performance utilizes aerobic 
pathways for energy production whereas maximal exercise utilizes both aerobic and 
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anaerobic glycolytic  pathways (Jean-St-et al., 2011).  In the maximal 100 m trial, the 
study found that remote IPC group was associated with an increase in the number of 
strokes without increases in heart rate. It was speculated that a reduced elevation in 
lactate may underlie the improvement in stroke rate and swimming speed by 0.70-s, 
which was statistically significant and corresponds to improvement seen with 2 year 
training program (Jean-St-Michel et al., 2011). Interestingly, samples of dialysate from 
the human subjects following remote IPC were used to perfuse mouse hearts undergoing 
myocardial ischemia. The data suggest that remote IPC released a protective factor into 
the bloodstream of the human subjects, which significantly reduced infarct size in mice 
exposed to myocardial ischemia. Using a randomized crossover study, Bailey et al. (2012) 
examined the effects of remote IPC or sham on lactate accumulation and running 
performance in 13 healthy men. The participants were made to undergo a graded 
treadmill running test consisting of five, 3 min stages after the application of bilateral 
upper leg remote IPC (4 cycles of 5 min of ischemia followed by 5 min reperfusion) and 
a sham trial (4 cycles of 5 min pressure at 20 mmHg followed by 5 min reperfusion). 
Lactate was assessed after each 3 minute stage. Following a 45 min rest that began after 
completion of the graded exercise test, subjects performed a 5 km running time trial. 
Subjects were instructed to choose their own running velocity and to complete the trial as 
fast as possible. The findings of this showed demonstrated a significant improvement in 
running performance that was preceded by remote IPC. For example, blood lactate levels 
during the graded running test were on average 1.1±0.1mmol/L lower with IPC versus 
sham (P=0.023). Moreover, subjects significantly reduced their 5-km running time trial 
duration by 34 sec after IPC versus sham (P=0.027). The authors concluded that IPC 
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improves running performance by reducing the onset of blood lactate accumulation which 
allowed for greater work rates. No differences were found in the oxygen consumption 
between the control and the remote IPC trials during the maximal running test whereas 
rate of perceived exertion was significantly lower during the IPC trial for the first 1000 km 
of five kilometer trial time (Bailey et al., 2012). The 5 km run trial was performed 90 min 
after the application of IPC, suggesting a prolonged window of action of IPC after its 
application. The mechanism suggested were via improvement in the KATP channels and 
improved mitochondrial ability to store lactate and oxidation of lactate in the muscle. 
While most studies discussed thus far have some benefits of IPC on exercise 
performance, Clevidence and colleagues (2012) report no improvement in cycling 
performance following remote IPC of the legs in 12 amateur cyclists. Subjects first 
completed a maximal graded cycle ergometer test beginning at a set power output of 100 
W sustained for 5 min. Then the power output was increased by 30 watt/min each min 
until the participant was exhausted. Several days after the maximal cycling test, subjects 
completed a submaximal cycling bout that was preceded by either remote IPC or control. 
During the IPC protocol, cuffs were inflated on the upper part of the thigh at 220 mm of 
HG for 5 min followed by 5 min of reperfusion. The performance test began with 30%, 
50% and 70% of their maximal power output in three stages of 5 min each. Blood samples 
were taken for analysis of glucose and lactate levels at the beginning and end of each 5 
min stage. There were no significant differences between the control and IPC trials with 
respect to any outcome variable (i.e., oxygen consumption, ventilation, respiratory 
exchange ratio, heart rate, and blood lactate). The authors concluded that an acute bout 
of remote IPC did not improve exercise performance    in competitive amateur-level 
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cyclists (Clevidence et al. 2012). The reasons to explain these negative results are not 
clear but probably involve the sample population studied. Because the athletes were well 
experienced cyclists, their maximal fitness capacity, lactate threshold, and cycling 
economy were already at a very high level and not conducive to further improvement 
using an acute bout of IPC. Perhaps different results would be demonstrated in novice 
cyclists. 
Taken together, a growing body of evidence suggests a favorable effect of remote 
IPC to improve exercise performance, particularly maximal performance. It appears that 
IPC may increase the use of lactate as a substrate which in turn can enhance exercise work 
rates. Whether IPC affects exercise economy is not clear. 
 
2.6 : LITERATURE REVIEW SUMMARY 
 
Remote IPC prepares the tissue against a sustained ischemic insult. It is a simple 
noninvasive procedure that can be done at the bed side. Remote IPC acts via complex 
mechanisms at cellular levels that provide the target organ an ability to tolerate ischemia. 
Laboratory trials have shown a reduction in myocardial infarct size, arrhythmias and 
improved post-surgical outcomes after application of remote IPC. The benefits of remote 
IPC have been translated to enhance exercise performance. The current research is aimed 
at understanding the effects of remote IPC on running economy. 
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3: METHODS 
 
The present study was conducted by Ms.Gungeet Kaur, a graduate student in the 
Department of Health & Nutritional Sciences at South Dakota State University under the 
mentorship of Dr. Gary Van Guilder. This section outlines the methodology of the 
present study. 
Specific Aim: To determine the effects of remote IPC on running economy. Based on the 
 
literature reviewed above, it is hypothesized that remote IPC will improve running 
economy. 
3.1 : EXPERIMENTAL DESIGN 
 
The study was a randomized single-blind crossover study in which subjects completed 
two submaximal running protocols to assess running economy in the absence and 
presence of remote bilateral leg IPC. 
 
Timeline: Following IRB approval, enrollment and data collection procedures were 
initiated in January 2015 and continued through the fall 2015 semester. We expect to 
complete all data collection procedures were completed by October 2015. 
 
 
3.2 : SUBJECT RECRUITMENT 
 
Nineteen healthy, recreationally active adult men and women between the ages of 18-40 
years were recruited for the study. 
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Inclusion Criteria 
 
 Injury free and recreationally active as determined by physical activity recall 
questionnaire. 
 Ability to jog on a treadmill at moderate to high intensity for 15 min 
 
 Any race or ethnicity 
 
 Men and women 
 
 Normotensive (blood pressure ≤140/90 mmHg) 
 
 Not taking any medications that could impact IPC 
 
 Apparently healthy and not meeting any of the exclusion criteria listed  below 
 
 
Exclusion Criteria 
 
 Current smoking or current use of tobacco-containing products 
 
 Past smoking or past use of tobacco-containing products 
 
 Recent injury precluding ability to run at moderate-high intensity 
 
 Pregnant or recent pregnancy 
 
 Use of cardiovascular or blood pressure-altering medications or any drug thathas 
been shown to impact IPC 
 History or evidence of hepatic, renal, or hematological disease; diabetes or 
cardiovascular disease 
 Recent use of ergogenic supplements 
 
 
 
Eligibility Screening: Potential research subjects that have expressed interest in 
volunteering for the study will be screened for eligibility using an American College of 
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Sports Medicine medical history form and a standard physical activity readiness 
questionnaire. Screening was conducted either on the phone, via email, or in person by 
the graduate student. Individuals that meet eligibility requirements were invited to 
undergo an informed consent with signature. 
 
3.3 : EXPERIMENTAL PROCEDURES 
 
Following eligibility screening and informed consent procedures, research subjects were 
randomized to participate in two separate testing sessions (i.e., remote IPC or sham) 
approximately 1-2 weeks apart and then crossover to complete the second trial (i.e., sham 
or remote IPC). Prior to each session, subjects were instructed to refrain from maximum 
effort exercise for the preceding 24 hours and to abstain from ingestion of any supplement 
or ergogenic aid that may enhance their performance. 
Session 1: Body height, weight, waist circumference, percent body fat, resting heart rate 
 
and blood pressure were measured during session 1. A description of these specific 
measurements is below. 
 
 
Anthropometric measurements 
 
Standing height and body weight were measured with a digital scale (Seca 876 digital 
scale, Seca Corporation, Hamburg, Germany). Abdominal waist circumference was 
assessed with a Gulick tape measured at the smallest part of the abdomen, above the 
umbilicus and below the xiphoid process to the nearest 0.1 cm at the end of normal 
expiration using standard procedures. Waist measurements were completed twice and 
averaged. Percent body fat was estimated by air displacement plethysmography 
(BODPOD, COSMED USA Inc., Illinois). 
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Cardiorespiratory fitness 
 
Maximum cardiorespiratory fitness was measured by open-circuit spirometry combined 
with indirect calorimetry (PARVO medics) in response to an incremental treadmill 
running protocol. Following a warm-up, subjects ran at a self-selected brisk pace at 0% 
incline for 2 minutes and then every two minutes thereafter, the workload was increased 
by raising the incline of the treadmill by 2% until volitional fatigue. Subjects were 
equipped with via a mouthpiece and nose clip, and a heart rate monitor to collect expired 
oxygen and carbon dioxide. Maximal oxygen uptake was determined if the subject reach 
age-predicted maximum heart rate combined with a respiratory exchange ratio >1.1. 
 
Hemodynamic measurements 
 
Non-dominant arm auscultatory resting systolic and diastolic blood pressure was 
measured using an appropriately sized stethoscope and sphygmomanometer (Diagnostic 
700 Series, American Diagnostic Corp, Hauppauge, NY) following 5 min of seated quiet 
rest using standard procedures. Resting blood pressure measurements were performed 
twice, separated by 3 minutes, and averaged. Resting heart rate was measured using a 60 
second radial pulse count. 
 
 
Remote IPC trial 
 
Following the baseline measurements described above, subjects completed either the 
remote IPC or sham trials and then perform a submaximal running trial. Three, 5 min 
cycles of leg ischemia each followed by 5 min of reperfusion was induced to stimulate 
bilateral remote IPC of the proximal thighs. To cause ischemia in the legs, a high pressure 
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cuff was inflated to 220 mmHg (EC20 rapid cuff inflator, DE Hokanson, Inc., Bellevue, 
WA) while the subjects rests in the supine position. Heart rate and blood pressure was 
measured during the last minute of each bout of ischemia. The total time to perform the 
remote IPC trial was approximately 30 minutes (i.e., 15 minutes of intermittent ischemia 
and 15 min of intermittent reperfusion). 
 
Sham trial 
 
The sham control trial consisted of the same procedure described above for the remote 
IPC trial except the pressure cuff were inflated to 20 mmHg to avoid ischemia and 
reperfusion. 
 
Submaximal Running Economy Trial 
 
Within 15 min following the remote IPC or sham trial, subjects were prepared to 
complete the submaximal running economy trial coupled with indirect calorimetry 
(TrueOne 2400, PARVO Medics, Sandy, UT). The submaximal running economy trial 
consisted of 3X5 min predetermined absolute running velocities with progressive 
increased workload at 0% grade. It was performed on a treadmill in the Health and 
Human Performance Laboratory. Each subject was set up with a heart rate monitor placed 
properly on the lower breastbone and watch for the wrist. Air flow and gas calibration of 
the indirect calorimeter was completed prior to testing. The investigator created a profile 
in the metabolic testing program using the participant’s personal information such as 
gender, age, height, and weight. Next, the mouth piece, mask, and head gear were placed 
on subject and adjusted to fit the individual during the trial. A nose piece was provided to 
prohibit airflow through the nasal cavity during the test. The mask connects to the 
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metabolic cart via tubing for the measurement of the volume of oxygen consumed and 
carbon dioxide produced during exercise. Two investigators were present during the 
testing throughout the study. Following calibration and set up, the investigators explained 
the protocol to the participant allowing him or her to ask questions before beginning the 
test. Then a brief 3 minute walking warm-up protocol at 80.5 m/min (3 mph) was 
completed. Immediately after the warm-up, the treadmill velocity was increased to a 
predetermined running velocity for 5 min. Thereafter, the treadmill velocity increased to 
13.4-26.8 m/min (0.5-1.0 mph) for 5 min and again by 13.4-26.8 m/min for a third 5 min 
stage. The total time completed for the submaximal running trial was 15 min. The 
participant then cooled down bywalking at a self-selected pace for 3-5 min. Steady-state 
oxygen consumption, respiratory exchange ratio, ventilatory rate, heart rate, and rating of 
perceived exertion were recorded every 15 sec during each exercise trial. Running 
economy was calculated by using an average of the oxygen uptake during the last minute of 
each 5 min running stage. Running economy was expressed as mlO2/kg/km and 
mlO2/kg/min at each running velocity for the sham and IPC trials. 
 
 
Blood Lactate 
 
A small sample of whole blood was obtained via finger prick from the index figure at 
baseline, during the warm-up phase, at the end of each 5 min running stage, and during 
the active cool-down phase to determine blood lactate levels (Lactate Plus, Nova 
Biomedical, UK). 
 
 
Session 2: At  least  one  week following session  1, subjects’  crossover  and completed 
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the alternate trial (either remote IPC or sham). Within 15 min after completion of the IPC 
trial, subjects completed the identical running protocol as performed in session 1. 
 
3.4 : TIME REQUIREMENT 
 
Because session 1 consisted of baseline measurements, it required more time from 
the research subjects compared with session 2. Baseline procedures lasted about 1 hour. 
The remote/sham IPC trial will require 30 minutes. The submaximal running trial required 
20 minutes with 15 minutes of preparation time. Collectively, with additional 
miscellaneous time, session 1 require approximately 145 min (2.4 hours). Session 2 
involved the remote/sham IPC followed by the submaximal running trial required 85 min 
(1.4 hours). 
 
3.5 : STATISTICAL ANALYSES 
 
Data were checked for normality and spread. Measures of central tendency were 
used to calculate baseline demographic subject data. A two-way repeated measures 
analysis of variance was used to determine differences in resting heart rate and blood 
pressure at the end of each 3 minute bilateral IPC and shame phase, and to determine 
differences in steady-state oxygen consumption, heart rate, minute ventilation, 
respiratory exchange ratio, and running economy between the submaximal running 
trials with and without IPC. To determine steady-state data, we averaged the final four 
data points for oxygen consumption, heart rate, minute ventilation, and respiratory 
exchange ratio from the 4th to 5th minute of each 5 minute exercise stage. Two-way 
repeated measures analysis of variance was used to determine differences in blood 
lactate across the three submaximal running trials with and without IPC. Running 
economy was determined by dividing steady-state oxygen consumption (ml/kg/min) at 
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each 5 min stage by the running velocity (m/min) and expressed as mlO2/kg/m and 
mlO2/kg/km. Statistical significance was set at P<0.05. Data are represented as 
means±SD and analyzed with SPSS version 20 (IBM, Inc.). 
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4: RESULTS 
 
Nineteen participants volunteered to participate in this study between March 2014 
and October 2015. One subject dropped out of the study and therefore the data was 
collected and analyzed for 18 subjects (12 men, 6 women). Each subject participated in 
three data collection sessions. On average, each session was at least one week apart. The 
maximum time between IPC and sham trials during the study was 3 months for one 
participant. All the participants completed 3 sessions. 
Subject characteristics are shown in Table 1. The mean age of participants was 27 
years with a mean BMI of 24.6 kg/m2. To make sure that participants met the inclusion 
criteria set for the study, each subject was screened before their participation using 
general health history form and a Physical Activity Readiness Questionnaire (Appendix 
II). The mean VO2 max was 51.8±5.4 ml/kg/min. Mean systolic blood pressure was 
114±14 mmHg and mean diastolic blood pressure was 67±7 mmHg. 
 
Table 4.1. Subject characteristics   
Variable Total Group (N=18) 
Sex, men/women 12 / 6 
Age, year 27  7 
Body mass, kg 74.5  10.8 
BMI, kg/m2 24.6  3.0 
Height, m 1.74  0.1 
Systolic BP, mmHg 114  14 
Diastolic BP, mmHg 67  7 
RHR, bpm 60  6 
VO2max, ml/kg/min 51.8  5.4 
Values are mean  SD. BMI: body mass index; BP: blood pressure; RHR, 
resting heart rate; VO2max, maximal oxygen consumption.  
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Subjective Experience with Bilateral Leg Ischemic Preconditioning 
 
Every participant was asked verbally about their experience during and after the IPC and 
sham trials. In general, the rapid increased pressure in the cuffs around the thighs was a 
relatively new experience for all of the subjects. They described the feeling initially 
during the 1st stage of IPC as slightly uncomfortable feeling of tingling and numbness, 
which eventually got better during the 2nd and 3rd stages of IPC. One participant 
experienced pain during IPC and dropped out of study. Overall, IPC was well tolerated 
by the participants and all the trials were successfully completed. All subjects also 
completed the submaximal running trials well. There was no incidence of injury during 
the study. 
 
 
Resting Hemodynamic Variables during Sham and Ischemic Preconditioning 
 
Resting Heart rate and blood pressure during the sham and IPC trials are presented in 
Table 2 below. Heart rate and blood pressure remained stable during the sham (P=0.79) 
and IPC (P=0.09) trials and there were no significant interactions between trials. There 
was a significant time interaction (P=0.04) in systolic blood pressure in the sham trial, 
such that systolic pressure at the end of third cuff phase was significantly lower compared 
with baseline. There were no other differences in blood pressure during the IPC or sham 
trials. 
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Table 4.2. Heart rate and blood pressure changes before and during three, 5 min bouts 
of bilateral sham and ischemic preconditioning of the legs. 
 
Heart rate, bpm 
 
Baseline 5 min 10 min 15 min 
Sham 
Ischemic 
preconditioning 
59±8 
 
63±11 
59±9 
 
60±9 
58±7 
 
58±9 
58±5 
 
59±9 
Systolic/Diastolic Blood pressure, mmHg 
 
Baseline 5 min 10 min 15 min 
Sham 
Ischemic 
preconditioning 
120/64±15/8 
 
120/65±16/7 
115/64±12/7 
 
117/65±13/7 
115/65±11/9 
 
117/67±114/7 
114/64±12/8* 
 
118/66±13/8 
Values are means±SD. *P<0.05 versus stage 1. 
 
 
 
Effects of Ischemic Preconditioning on Incremental Treadmill Running 
 
Table 3 demonstrates steady-state heart rate, minute ventilation, and respiratory exchange 
ratio at the end of each 5 min submaximal running stage between the sham and IPC trials. 
While heart rate, minute ventilation, and respiratory exchange ratio progressively 
increased with incremental running, there were no significant interactions between trials. 
Figure 1 and 2 reports the changes in oxygen uptake and heart rate at each minute of the 
15 min incremental running test between the sham and IPC interventions, respectively. 
There were significant increases (both P<0.001) in oxygen uptake and heart rate during 
each running test. However, there was no time X trial interaction in oxygen uptake or 
heart rate. Likewise, figure 3 depicts steady-state oxygen consumption for each 5 min 
running stage. In the sham running trial, oxygen consumption progressively increased 
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22% (P<0.001) from 34.1 (stage 1) to 41.6 ml/kg/min (stage 3) and 20% (P<0.001) from 
 
34.3 (stage 1) to 41.4 ml/kg/min (stage 3) in the IPC running trial. There was no time X 
trial interaction in steady-state oxygen. 
 
 
Table 4.3. Steady-state heart rate, minute ventilation and respiratory exchange ratio during 
incremental treadmill running between sham and IPC trials. 
  
Trial 
 
P value 
Sham  IPC  
Stage 1     
Heart rate (bpm) 152±9  151±11 0.756 
VE (l/min) 66±15  66±15 0.879 
RER 0.909±0.040  0.906±0.035 0.766 
Stage 2     
Heart rate (bpm) 165±8  164±10 0.629 
VE (l/min) 78±18  79±17 0.363 
RER 0.937±0.037  0.935±0.041 0.783 
Stage 3     
Heart rate (bpm) 174±6  174±8 0.999 
VE (l/min) 90±19  91±18 0.768 
RER 0.968±0.036  0.958±0.036 0.058 
Data represent mean±SD. IPC, ischemic preconditioning; VE, minute ventilation; RER, 
respiratory exchange ratio. 
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Figure 4.4. Minute oxygen uptake (ml/kg/min) changes during the 3 staged incremental 
running tests for the sham and IPC trials. 
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Figure 4.5. Minute heart rate changes (bpm) during the 3 staged incremental running 
tests for the sham and IPC trials. 
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Figure 4.6. Steady-state oxygen uptake at the end of each 5 min running stage between 
the sham and IPC trials. *P<0.01 versus corresponding stage 1 trial. †P<0.01 versus 
corresponding trial in stage 1 and stage 2. 
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Running Economy 
 
Running economy data between the sham and IPC trials are shown in Figure 4. In the 
sham running trial, economy remained unchanged (P=0.232) from 201.6 (stage 1) to 
204.0 ml/kg/km (stage 3). Similarly, economy did not change in the IPC trial (P=0.129; 
from 202.8 to 203.1 ml/kg/km). There was no time X trial interaction (P=0.647) in 
running economy. 
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Figure 4.7. Running economy at the end of each 5 min incremental running stage in the 
sham and IPC trials. 
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Lactate 
 
Blood lactates are shown in Figure 5. There was a significant increase in lactate during 
the exercise trials for both sham (P=0.012) and IPC (P=0.001). For example, lactate 
increased from 3.4±1.6 to 5.3±2.4 mmol/l in the sham trial and from 2.9±1.2 to 5.7±2.2 in 
the IPC trial. Post hoc analysis demonstrated that lactate at stage 3 was significantly 
greater compared with stage 1 for both the sham and IPC trials. However, there was no 
time X trial interaction in blood lactate. 
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Figure 4.8. Blood lactate at the end of each 5 min incremental running stage in the sham 
and IPC trials. *P<0.01 versus corresponding stage 1 trial. 
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5: DISCUSSION 
 
Summary, Conclusion(s), Limitations, Alternative Hypotheses, Implications for 
Practice 
 
In the present study, bilateral leg ischemic preconditioning did not affect running 
economy in recreationally active young healthy adults. These findings are based on 
similar steady-state oxygen consumption, heart rate, minute ventilation, and respiratory 
exchange ratio during incremental treadmill running between the sham and 
preconditioning trials. Thus, the findings of the study do not support our proposed 
hypothesis and are in contrast to previous studies reporting aerobic exercise performance 
benefits with ischemic preconditioning of the legs. Collectively, these findings imply that 
preconditioning may not be the best technique to improve running economy in 
recreationally active people. 
By and large, previous studies have demonstrated that ischemic preconditioning 
of the legs enhances running, swimming and cycling endurance exercise performance at 
vigorous exercise intensities but does not influence performance at submaximal exercise 
intensities. For example, work by Jean et al. on elite swimmers indicated that 
preconditioning significantly reduced the time to complete a maximal 100 m swim (an 
average of 7 sec reduction). However, there was no performance benefit in submaximal 
swimming performance as the authors reported that swimming velocity, heart rate, and 
the workload at the onset of blood lactate accumulation was similar in the control and 
conditioning trials 10. In a different study, De Groot and colleagues reported an 
improvement in cycling maximal oxygen uptake (3%) and power output with bilateral leg 
preconditioning during an incremental cycling test but did not demonstrate any 
improvement in submaximal performance. Indeed, steady-state oxygen consumption, 
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heart rate, minute ventilation, and respiratory exchange ratio were similar with and 
without preconditioning in the cyclists 9. Findings from Clevidence and coworkers (2012) 
also support the notion that preconditioning does not influence submaximal exercise 
performance in cyclists. In 12 male cyclists, submaximal heart rate, oxygen uptake, 
ventilation, respiratory exchange ratio, and blood lactate were not different at 30, 50, and 
70% of VO2max relative exercise intensities between condition and control trials 
11. 
Collectively, these data suggest that because steady-state oxygen uptake and the 
workload and/or velocity appear to be similar with and without preconditioning in both 
swimmers and cyclists, exercise economy would also be expected to remain unchanged. 
The findings of the present study support this as they provide the first evidence to suggest 
that economy of running is nearly identical in the absence and presence of ischemic 
preconditioning. For both trials in the present study, the oxygen cost of running at each 
velocity was less than 1% different between trials, providing strong support that ischemic 
precondition of the legs does not improve running economy. In line with the oxygen cost 
of running data, we also demonstrated that heart rate, minute ventilation, and substrate 
utilization – as estimated by the respiratory exchange ratio – were unaffected by 
preconditioning during the incremental running protocol. Moreover, blood lactate 
concentrations at the end of each steady-state running stage were largely unaffected by 
preconditioning, arguing for the notion that lactate production and/or metabolism are not 
contributing to the performance benefits that other groups have reported. It should be 
noted however, that Bailey et al. did show that the onset of blood lactate accumulation 
increased during submaximal running at moderate to vigorous exercise velocities and this 
was associated with faster 5 km running performance. Clearly, more sophisticated 
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experiments are needed to identify the role that ischemic preconditioning has on lactate 
metabolism with respect to exercise performance. 
It is thought that the factors that modify running economy take time to develop 
over the course of a runner’s career, which is likely to be a primary reason why we did 
not show improved running economy with a single preconditioning intervention. Running 
economy depends on various factors including training, exercise environment, and 
biomechanics 12. For example, it appears that muscle and joint coordinated movement is 
particularly important in determining economy of movement. Several muscles and joints 
of the body coordinate for the production of movement at a required energy cost. Altering 
the mechanics of joint stability and differences in muscle stiffness can either increase or 
reduce the energy cost of submaximal exercise. Improving skeletal muscle strength and 
power has been shown to enhance exercise economy and this performance benefits are 
due in part to changes in the stiffness of the working muscles and tendons (Dumke et al. 
2010). Altitude training has also been shown to improve running economy. Saunders and 
colleagues (2004) showed that 20 days of live high, train low altitude training lowered 
the aerobic cost of running in elite runners, however, the improved economy could not be 
explained by the physiological adaptations that are common to altitude. 
It has been suggested that the performance benefits of preconditioning may be due 
to a placebo effect. Marocolo et al. (2015) recruited 15 amateur swimmers underwent a 
control, bilateral arm ischemic preconditioning, or sham trial prior to a maximal 100 m 
swim trial. The study however, made an exception by informing their participants that 
sham and preconditioning trials would improve performance. The study showed that 
preconditioning (0.036) improved performance compared to the control trial, but did not 
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affect performance relative to the sham trial, suggesting that the better swim performance 
is due to a placebo effect (Marocolo et al., 2015). The potential for a placebo effect has 
also been shown by this same group of investigators for resistance training (Marocolo et 
al., 2015). 
There are some important limitations of the present study. First, we only 
investigated the effect of the first window of benefits of preconditioning on running 
economy. The second window of protection, which begins 12 hours after the conditioning 
stimulus and last for up to 72 hours, is due in part to gene transcription of new effector 
proteins that may contribute to exercise performance benefits in athletes. Future studies 
investigating these potential effects are warranted. Secondly, the present study was 
limited to the influence of preconditioning on the economy of running and cannot be 
generalized to economy changes of other modes of aerobic exercise. Thirdly, 17/18 
subjects were of Caucasian ethnicity and the findings here cannot be applied to other 
ethnic groups. Fourth, it is possible that bilateral leg ischemic preconditioning may over 
condition the skeletal muscle contributing to mild reperfusion injury, which would be 
expected to interfere with the delivery of blood flow and energy substrates to the working 
muscle. To address this concern, future studies should consider conditioning one limb 
instead of two and to remote condition the arm instead of the legs. Interestingly, there are 
studies that have reported that ischemic conditioning may be detrimental to exercise 
performance, particularly maximal aerobic exercise. In 15 amateur cyclists, Paixão et al. 
showed that preconditioning the legs significantly reduced maximal and mean anaerobic 
power compared to no preconditioning 13. To date, however, the most studies have 
reported either improved or no changes in exercise performance with ischemic 
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precondition, albeit these studies have mostly focused on aerobic exercise. Lastly, we 
directed each participant to maintain the same level of activity between trials and to avoid 
running training for the duration of the study. However, we cannot rule out that other 
lifestyle factors (e.g., exercise habits and nutrition intake) may have influence the 
findings. Nevertheless, the single-blind, randomized crossover design employed in the 
present study suggests that, despite these limitations, ischemic preconditioning does not 
affect submaximal running economy in recreationally active runners. 
 
 
Conclusion 
 
The results of the study did not support the hypothesis that bilateral leg ischemic 
preconditioning improves running economy in recreationally active adults. Further 
studies should be conducted to elucidate the effect of preconditioning modalities on other 
the energy cost of other sports (i.e., cycling, swimming) and to investigate the potential 
exercise performance benefits that may be incurred by the second window of protection. 
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Appendix-I 
Participant Informed Consent Form 
Participation in a Research Project 
South Dakota State University 
Brookings, SD 57007 
 
 
      Department of Health and Nutritional Sciences 
 
Project Director: Dr. Gary P. Van Guilder Phone No: 605-688-4082 
 
E-mail: gary.vanguilder@sdstate.edu Date: 12/12/14 
 
 
Please read (listen to) the following information: 
 
This is an invitation for you,  , to participate in a research 
project under the direction of Dr. Gary P. Van Guilder, an Exercise Science Professor. 
 
1.   The project is entitled:  Effect of Ischemic Preconditioning on Running Economy. 
 
2.  The purpose of the project is to determine the effects of remote ischemic 
preconditioning on running economy. Preconditioning is a process that helps your 
body become more resistant against physical stress. Some studies have shown that 
preconditioning may benefit exercise   performance but others have not. Our goal 
will be to identify if preconditioning improves your running economy, which is an 
important component of exercise performance. 
 
 3.   If you consent to participate, you will undergo three research sessions separated at   
least 1 week. Each research session will require 45 minutes of your time.  Each 
session described below. 
 
Session 1: During the first testing session, we will measure your resting heart rate and 
blood pressure, body height, weight, waist circumference, and percent body fat. You will 
also undergo a fitness test on a treadmill. 
 
Measurement of resting heart rate and blood pressure: You will be rest quietly for 5 
minutes before we measure your heart rate and blood pressure. Resting heart rate will be 
measured using a 60 second arterial pulse count. To measure your blood pressure, we will 
place an inflatable cuff around your upper arm. We will inflate the cuff to a high pressure. 
Then we will release the pressure slowly while we listen for the sound of your heartbeat. 
We will repeat this measurement twice separated by 2-3 minutes. 
 
Measurement of body composition: We will measure your height and body weight using 
digital scale. Abdominal waist circumference will be assessed with a tape measured at the 
smallest part of the abdomen. Percent body fat and muscle mass will be estimated by air 
displacement plethysmography. During this procedure, you will be placed in a small 
enclosed chamber and instructed to sit quietly for 2 minutes. This procedure does not 
require you do anything except sit quietly. 
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Remote Ischemic Preconditioning 
Preconditioning your muscles has been shown to improve their function. It has also been 
shown to protect the heart. It can be caused by stopping blood flow to a tissue (e.g. 
muscle) for very short periods of time (i.e., a few minutes) and then letting blood flow back 
into the tissue for an equal amount of time. Stopping blood flow in this manner does not 
damage the tissue. You will undergo preconditioning of your leg muscles. To cause 
preconditioning in the legs, a pressure cuff will be inflated around both upper thighs to a 
pressure similar to a blood pressure measurement while you rest on a hospital bed. Three, 
5 minutes inflations followed by three, 5 minute deflations will occur. We will measure your 
heart rate and blood pressure during the last minute of each 5 minute inflation-deflation 
cycle. 
 
Control trial 
The control trial will consist of the same procedure described above for the remote 
ischemic perconditioning trial except the pressure cuff will be inflated to a low pressure to 
avoid stopping blood flow to the legs. 
 
Once you have completed either the preconditioning or the control trial, you will perform a 
15 minute light to moderate intensity running trial on a treadmill. 
 
Light to Moderate Treadmill Running Trial 
 
Within 15 minutes following the preconditioning or control, you will be prepared to complete 
the treadmill running protocol in the Health and Human Performance laboratory. We will be 
measuring the amount of oxygen that you breathe and use to perform the exercise, similar 
to the procedures described above for your maximum fitness test. To do this, we will equip 
you with a mouthpiece that will collect your expired air. The air that we collect will be 
analyzed for oxygen and carbon dioxide. To ensure that we collect your air from your 
mouth, a nose clip will be placed over your nostrils. You will need to run with the 
mouthpiece and nose clip for 15 minutes. Once you are set up with the mouthpiece and 
nose clip, you will walk for 3 minutes to warm up at a walking speed of 3 mph.  Immediately 
after the warm-up, we will increase the treadmill speed to 6 mph. You will maintain this 
running speed for 5 min. Thereafter, the treadmill speed will increase to 7 mph for 5 min. 
Lastly, we will increase the treadmill speed to 8 mph for 5 min for a total of 15 minutes of 
running. Then you will cool down by walking at a self-selected pace for 3-5 min. We will 
record the amount of oxygen you use, your heart rate, breathing rate, and running economy 
every minute during each exercise trial. 
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At end of each 5 minute stage, you will rest for a short period of time (~1 minute) and we 
will obtain a small drop of blood from your finger using a finger prick to measure the level 
of lactate. Lactate is a byproduct of your muscle cells that tells us how hard you are 
exercising. We will perform the lactate measurement 6 times during each exercise test 
(prior to the start of exercise, at the end of each running stage, and twice during cool down). 
Your finger will be sterilized with alcohol swabs prior to each lactate measurement. The 
investigator will wear protective gloves. 
 
Session 3: At least one week following session 2, you will complete the alternate trial 
(either remote preconditioning or control). Within 15 minutes after completion of that trial, 
you will complete the identical running protocol as performed in session 2. 
 
1. Participation in this project is voluntary. You have the right to drop out at any time without 
penalty and you have the right not to participate in any aspect of the study. Your grade for 
any class will not be affected if you volunteer for this project. You will not get extra credit 
by volunteering for this study. If you have any questions, you may contact Dr. Van Guilder 
at the phone number listed at the end of this form. 
 
2. There are minimal risks to you if you volunteer for this project. First, blood pressure 
measurements involve inflating an upper arm cuff to a high pressure for 20 seconds. You 
may experience some mild discomfort during this test. Although obtaining a sample of 
whole blood (one drop, or about 40µl) via a small finger prick is safe and confers minimal 
physical risk, there is a chance that you will experience mild pain for a few seconds during 
the procedure. In addition, the finger prick may cause tiny bruising on the skin that should 
subside in a day. There is a small risk of infection at the finger prick site. With respect to 
preconditioning your legs, the procedure is quick and poses no more than minimal risk to 
you. Blood flow to your legs will be stopped for 5 minutes using a high pressure cuff. As a 
result, you will experience tight squeezing of the upper legs that may be mildly 
uncomfortable. Although, generally painless, you may experience mild numbness of the 
legs for 5 minutes. Lastly, when the blood pressure cuff is deflated, you will experience a 
rush of blood flow through the legs. The skin will redden and feel warm with transient 
feelings of ‘pins and needles’ in the skin as blood flow returns to normal. These feelings 
should subside within 2 minutes. 
 
3.By volunteering for this study you will learn the impact of preconditioning on your ability 
to run on a treadmill. You will also learn your body composition, maximal cardiorespiratory 
fitness, and your running economy. 
 
4.You will not be financially compensated by volunteering for the project. There is no 
financial cost to you for volunteering for this project. 
5. Your data is strictly confidential. When the data and analysis are presented, you will not 
be linked to the data by your name, title or any other identifying item. To keep your identify 
protected we will assign you a number code. This code will only be available to the 
research team. The code will link you to the study instead of your name. Your information 
will be kept confidential in a University computer. The computer is password protected. 
Copies of data forms will be stored in a locked filing cabinet. 
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Participant's Signature  Date    
 
 
 
Project Director's Signature  Date    
 
If you have any questions regarding this study you may contact the Project Director, Dr. 
Gary Van Guilder, using the contact information presented below. If you have questions 
regarding your rights as a participant, you can contact the SDSU Research Compliance 
Coordinator at (605) 688-6975 or SDSU.IRB@sdstate.edu. 
 
Project Director: 
Gary P. Van 
Guilder, Ph.D. 
Assistant 
Professor 
Department of Health and 
Nutritional Sciences South Dakota 
State University 
Box 2203, Intramural 116 
Brookings, SD 57007 
Phone: 605-688-4082 
Email: gary.vanguilder@sdstate.edu 
 
This project has been approved by the SDSU Institutional Review Board, Approval 
No.: IRB- 1312013-EXP 
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            Appendix-II 
Vascular Protection Laboratory       
Department of Health and Nutritional Sciences 
 Eligibility Screening Questionnaire 
 
        This Eligibility Screening Questionnaire is necessary to help us understand any potential risks 
associated with your eligibility in participating in a research study. All information you provide is 
personal and confidential. 
 
GENERAL INFORMATION 
 
Name 
  
Address 
  
City 
  
State 
  
Zip code 
  
Phone 
(home) 
  
Phone 
(work) 
  
Email 
  
 
  
Age 
  
Sex 
 
Hispanic 
Identity 
 
Race 
 
 
Emergency Contact 
 
Phone 
 
 
MEDICAL DIAGNOSES 
                           Do you have or have you ever had any of the following? Please check yes or no. 
 
Con
diti
on 
Yes No Condition Yes No 
Heart attack   Pulmonary disease   
      
Chest pain   Heart valve problems   
Asthma   Heart murmur   
Anemia   Rheumatic fever   
Cardiovascu
lar surgery 
  Phlebitis   
Currently 
pregnant 
  Emboli (blood clot)   
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Emphysema   Coronary artery disease   
Diabetes 
(type 1 or 2) 
  Stroke   
Cancer   Peripheral artery disease   
Please list any additional special conditions. 
   
   
 
 
 
Major Risk Factors Yes No 
Not 
sure 
 
Are you a man over the age of 45 or a woman over the age of 55? 
    
Are you postmenopausal? 
    
Has your father or brother experienced a heart attack before age 55? 
    
Has your mother or sister experienced a heart attack before the age of 65? 
    
Has your doctor ever told you that you might have high blood pressure? 
    
Is your cholesterol above 200 mg/dl? 
    
Do you have prediabetes (blood sugar ≥100 mg/dl)? 
    
Are you physically inactive (less than 30 minutes of physical activity on at least 3 
days/week)? 
    
Do you currently smoke or have you quit smoking in the last 6 months? 
    
Are you > 20 pounds overweight? 
    
 
 
 
 
SIGNS/SYMPTOMS SUGGESTIVE OF CARDIOVASCULAR AND 
PULMONARY DISEASE Yes No 
Pain discomfort (or angina equivalent) in the chest, neck, jaw, arms, or other areas that 
may be due to ischemia (decreased blood flow) 
  
Shortness of breath at rest or with mild exertion 
  
Dizziness or fainting at rest or with mild exertion 
  
Orthopnea/paroxysmal nocturnal dyspnea (labored breathing at night or while 
sleeping) 
  
Edema (excessive accumulation of tissue fluid usually in the ankles and lower legs) 
  
Palpitations or tachycardia (sudden rapid heartbeat) 
  
Intermittent claudication (lameness due to decreased blood flow) 
  
Known heart murmur (abnormal heart sound) 
  
Unusual fatigue 
  
 
 
Cardiovascular diseases include cardiac, peripheral vascular or cerebrovascular disease 
Pulmonary diseases include chronic obstructive pulmonary disease, asthma, interstitial lung disease, or 
cystic fibrosis, Metabolic diseases includes Type 1 or 2 Diabetes mellitus, thyroid disorders, renal or liver .
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MEDICATIONS 
Please list any medications you are currently taking including prescriptions medications and over the counter 
medications, dietary supplements, vitamins, minerals, etc. 
 
Medication Dose and frequency 
  
  
  
  
  
  
  
 
 
  Please list any dietary supplements you are currently taking including, but not limited to vitamins, minerals, 
energy drinks, weight loss/weight gain supplements etc. 
 
Dietary supplement Dose and frequency 
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Ischemic Preconditioning Running Economy Study 
Vascular Protection Laboratory 
South Dakota State University 
Block Randomization Sheet 
Subjet Trial 1                          Trial 2  
    1. Sham IPC 
    2. IPC                           Sham 
    3. IPC                           Sham 
    4. Sham IPC 
    5. IPC                           Sham 
    6. Sham IPC 
    7. IPC                           Sham 
    8. Sham IPC 
    9. IPC                           Sham 
10. IPC                           Sham 
11. Sham IPC 
12. Sham IPC 
13. IPC                           Sham 
14. Sham IPC 
15. Sham IPC 
16. IPC                           Sham 
17. IPC                           Sham 
18. Sham IPC 
19. IPC                           Sham 
20. IPC                           Sham 
21. IPC                           Sham 
22. Sham IPC 
23. Sham IPC 
24. Sham IPC 
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Anthropometric and Hemodynamic Data Sheet Vascular 
Protection Laboratory 
South Dakota State University 
 
 
Subject ID: 
 
Tech: 
 
Date: 
 
Trial: 
 
 
 
Variable 
 
Value 
 
Age, year 
 
 
Height, cm 
 
 
Weight, kg 
 
 
BMI, kg/m2 
 
 
Obesity status 
 
 
Waist circumference, cm 
 
 
Hip circumference, cm 
 
 
WHR 
 
 
WHR status 
 
 
Body fat, % 
 
 
Resting heart rate, bpm 
 
 
Resting blood pressure 1, mmHg 
 
/ 
 
Resting blood pressure 2, mmHg 
 
/ 
 
Blood pressure classification 
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Appendix V 
Ischemic Preconditioning Protocol Vascular 
Protection Laboratory 
 
 
Subject ID: 
 
Tech: 
 
Date: 
 
Trial: 
 
Pha
se 
Time (min) Ischemia/Reperfusion Heart Rate, BPM 
Blood 
Press
ure, 
mmH
g 
Bas
elin
e 
0 --- 
  
1 1-5 minutes Ischemia: Cuff inflated --- -
-
- 
2 5-10 minutes Reperfusion: Cuff deflated 
 
/ 
3 10-15 minutes Ischemia: Cuff inflated --- -
-
- 
4 15-20 minutes Reperfusion: Cuff deflated 
 
/ 
5 20-25 minutes Ischemia: Cuff inflated --- -
-
- 
6 25-30 minutes Reperfusion: Cuff deflated 
 
/ 
 
Cuff placement instructions: 
Place pressure cuffs on the upper thigh of both legs as high as possible (running economy study only). All 
other studies place only one cuff on dominant upper arm. 
Ischemic preconditioning trial: 
Inflate pressure cuffs to 220 mmHg to cause ischemia for 5 minutes, followed by 5 minutes of cuff deflation. 
Repeat 3 times. Record heart rate and blood pressure during last minute of reperfusion phase. 
Sham control trial: 
Inflate pressure cuffs to 20 mmHg to avoid ischemia for 5 minutes, followed by 5 minutes of cuff deflation. 
Repeat 3 times. Record heart rate and blood pressure during last minute of reperfusion phase. 
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Appendix VI 
Ischemic Preconditioning Running Economy 
Study Vascular Protection Laboratory 
Subject ID: Tech: Date: Trial: 
Start Baseline and Warm-up 
 
Level 
Protocol 
Time 
(min) 
 
Speed, mph 
(m/min) 
 
HR (bpm) 
 
RPE 
 
Lactate 
(mmol/l) 
 
Sitting 
rest 
 
-5-4 
 
--- 
  
--- 
 
Warm-up 
1 
-4-2 3.0 
 
--- 
 
 
Warm-up 
2 
 
-2-0 0.5 less 1
st 
run speed 
  
--- 
 
Start Exercise 
 
1 
 
0-5 
 
5.5 (147) 
   
  
 
2 
 
5-10 
 
6.0 (161) 
   
  
 
3 
 
10-15 
 
6.5 (174) 
   
  
S
ta
rt 
R
e
c
o
v
e
r
y 
 
 
Recovery 
 
 
15-20 
 
 
2.0-3.0 
  
 
--- 
 
 
 
At the end of each 5 min stage, instruct the subject to straddle the belt and immediately click ‘Pause’  on 
computer. Obtain and record the lactate reading. Select ‘Events’ and record the lactate reading in the ‘RPE’ text 
boxy as, for example ‘STG1L3.3, where STG stands for ‘stage’, ‘1’ stands for Level 1, ‘L’ stands for lactate and 
its value. Once the lactate reading has been obtained and recorded, increase treadmill speed to the next level 
and instruct the subject to resume running and immediately select ‘Resume’ on the computer. Repeat steps 
for stages 2-3. 
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Obtain lactate within 30-45 seconds. Do not change to the treadmill intensity to the next level until you have 
obtained an accurate lactate reading. Repeat the lactate measurement if necessary. 
 
